<DOC>
	<DOCNO>NCT01595685</DOCNO>
	<brief_summary>The goal chronic hepatitis B ( CHB ) treatment complete permanent eradication hepatitis B virus ( HBV ) patient 's body , best represent serum HBsAg loss accompany undetectable serum HBV DNA level . While recently approve nucleos ( ) ide analogue ( NA ) mark antiviral potency induce HBV DNA undetectability majority patient prolong treatment , NA need give long term , almost indefinitely , case suppress HBV DNA therapy . For example , even HBeAg-loss potent NA , suppression serum HBV DNA undetectable level sustain 23 % -37 % 24 week treatment . Thus , continuous therapy NA HBsAg clearance remain necessary majority case . The recent availability commercial quantitative assay serum hepatitis B surface antigen ( HBsAg ) enable quantitative HBsAg use biomarker prognosis treatment response CHB . It suggest HBsAg decline lamivudine entecavir therapy slow less pronounced compare interferon treatment , despite high effect HBV DNA suppression . Based HBsAg kinetics , estimate predict median time HBsAg loss patient treat lamivudine entecavir 30 year . Thus , treatment induce rapid decline HBsAg would clear advantage reduce treatment duration require achieve HBsAg-loss . Interestingly , recent preliminary study , 24-weeks treatment telbivudine induce HBsAg decline comparable pegylated interferon treatment . Although head-to-head trial compare NAs induce HBsAg decline , previous study consistently suggest decline HBsAg great telbivudine treatment compare lamivudine entecavir . Thus , clinical trial , investigator investigate whether telbivudine effective inducing HBsAg decline compare entecavir HBeAg-positive CHB patient achieve undetectable serum HBV DNA precede entecavir treatment .</brief_summary>
	<brief_title>Telbivudine Versus Entecavir Reducing Serum HBsAg Levels Patients With HBeAg-positive Chronic Hepatitis B</brief_title>
	<detailed_description>A single-center randomized active-controlled open-label superiority trial - Patients randomly assign 1:1 receive telbivudine ( 600 mg/day ) ongoing entecavir ( 0.5 mg/day ) 48 week . - Eligible patient randomize use block permute treatment assignment stratification HBsAg level ( 1,000 IU/mL-5,000 IU/mL ≥5,000 IU/mL IU/mL ) entecavir treatment duration ( 1 year-2 year , ≥2 year ) . - Because 98 % Korean patient CHB HBV genotype C,9 HBV genotype determine regarded stratification factor . - There interruption entecavir therapy randomization . - Patients ' treatment information retrospectively collect entecavir treatment phase well ( DNA change , HBeAg status , HBsAg titre , ALT , treatment duration . etc ) - Patients screen within 4 week randomization determine study eligibility .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>All HBsAg titer &gt; 1,000 IU/mL HBeAg positive study entry baseline ETV treatment HBV DNA undetectable ( &lt; 15 IU/mL ) least 2 occasion 3 month apart Treatment entecavir ( 0.5 mg/day ) 1 year Patient ambulatory . Patient able willing give inform consent . Any Prior exposure oral nucloes ( ) ide analogue entecavir Prior exposure interferon pegylated interferon Cirrhosis ChildPugh score ≥8 Hepatocellular carcinoma Identified suspect Other malignancy Prior organ transplantation Under immunosuppressive agent Renal insufficiency ( serum creatinine &gt; 1.4 ) Pregnant woman willing pregnant woman man</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HBeAg-positive</keyword>
</DOC>